or Try an Advanced Search...

    Technical Analysis for APLT - Applied Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 4.71 -2.28% -0.11
    APLT closed down 2.28 percent on Wednesday, May 8, 2024, on 26 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 9
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical APLT trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    20 DMA Support Bullish -2.28%
    Wide Bands Range Expansion -2.28%
    Up 3 Days in a Row Strength -2.28%
    Up 4 Days in a Row Strength -2.28%
    Up 5 Days in a Row Strength -2.28%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.88%
    Crossed Above 20 DMA Bullish -1.88%
    Doji - Bearish? Reversal -1.88%
    Wide Bands Range Expansion -1.88%
    Older End-of-Day Signals for APLT ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 9 hours ago
    Possible NR7 about 9 hours ago
    60 Minute Opening Range Breakdown about 10 hours ago
    Down 2 % about 10 hours ago
    Down 1% about 13 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    APLT Chart by TradingView
    Basic chart:

    Profile

    Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Organ Systems Diabetes Cardiovascular Disease Diabetes Mellitus Diabetic Retinopathy Cardiomyopathy Myopathy Retinopathy Peripheral Neuropathy Preclinical Stage Product Stage Products Diabetic Peripheral Neuropathy Lactose Novel Products Preclinical Stage Products

    Is APLT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference
    Apr 15 Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
    Apr 4 Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
    Apr 1 Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
    Apr 1 Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Mar 28 UPDATE 1-US FDA extends review of Applied Therapeutics' genetic disease drug
    Mar 28 Applied Therapeutics gets extension of FDA review for rare disease drug
    Mar 28 Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
    Mar 22 Applied Therapeutics files to sell 14.29M common shares for holders
    Mar 13 Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
    See more APLT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.39
    52 Week Low 1.18
    Average Volume 1,300,288
    200-Day Moving Average 3.27
    50-Day Moving Average 5.70
    20-Day Moving Average 4.66
    10-Day Moving Average 4.53
    Average True Range 0.33
    RSI (14) 43.50
    ADX 17.87
    +DI 19.21
    -DI 19.59
    Chandelier Exit (Long, 3 ATRs) 4.72
    Chandelier Exit (Short, 3 ATRs) 5.15
    Upper Bollinger Bands 5.30
    Lower Bollinger Band 4.01
    Percent B (%b) 0.54
    BandWidth 27.72
    MACD Line -0.24
    MACD Signal Line -0.32
    MACD Histogram 0.077
    Fundamentals Value
    Market Cap 363.75 Million
    Num Shares 77.2 Million
    EPS -1.25
    Price-to-Earnings (P/E) Ratio -3.77
    Price-to-Sales 20.14
    Price-to-Book 4.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.01
    Resistance 3 (R3) 5.03 4.95 4.96
    Resistance 2 (R2) 4.95 4.87 4.94 4.94
    Resistance 1 (R1) 4.83 4.83 4.79 4.81 4.93
    Pivot Point 4.75 4.75 4.73 4.74 4.75
    Support 1 (S1) 4.63 4.67 4.59 4.61 4.49
    Support 2 (S2) 4.55 4.63 4.54 4.48
    Support 3 (S3) 4.43 4.55 4.46
    Support 4 (S4) 4.41